Contrast agents for hepatic magnetic resonance imaging

Topics in Magnetic Resonance Imaging

Volumn 13, Issue 3, 2002, Pages 117-150

  Morana, Giovanni ^a   Grazioli, Luigi ^a   Testoni, Marco ^a   Caccia, Paolo ^a   Procacci, Carlo ^a  

^a Policlinico Universitario gB Rossi   (Italy)

Author keywords

Contrast media; Liver; Magnetic resonance; Neoplasms

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE; GADOVERSETAMIDE; GADOXETIC ACID; MANGAFODIPIR; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

BINDING KINETICS; CELLULAR DISTRIBUTION; CONTRAST ENHANCEMENT; CONTRAST RADIOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

AGED; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIOGRAPHIC IMAGE ENHANCEMENT; SENSITIVITY AND SPECIFICITY;

EID: 0036620244     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002142-200206000-00002     Document Type: Review

References (171)

1. Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: Characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 1994;190:417-423.
2. Grebe P, Schild H, Kreitner KF, et al. The differentiation between benign and malignant liver lesions by unenhanced MRI. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1994;161:412-416.
3. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: Evaluation of the efficacy of gadobenate dimeglumine in MR imaging - A multicenter phase III clinical study. Radiology 2000;215:727-736.
4. Hamm B, Fischer E, Taupitz M. Differentiation of hepatic heman-giomas from metastases by dynamic contrast-enhanced MR imaging. J Comput Assist Tomogr 1990;14:205-216.
5. Semelka RC, Shoenut JP, Kroeker MA, et al. Focal liver disease: Comparison of dynamic contrast-enhanced CT and T2-weighted fat-suppressed, FLASH, and dynamic gadolinium-enhanced MR imaging at 1.5 T. Radiology 1992;184:687-694.
6. Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: Evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 1997;205:721-728.
7. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984;16:167-172.
8. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol 2001;36:632-641.
9. Nakayama M, Yamashita Y, Mitsuzaki K, et al. Improved tissue characterization of focal liver lesions with ferumoxide-enhanced T1 and T2-weighted MR imaging. J Magn Reson Imaging 2000;11:647-654.
10. Liou J, Lee JK, Borrello JA, et al. Differentiation of hepatomas from nonhepatomatous masses: Use of MnDPDP-enhanced MR images. Magn Reson Imaging 1994;12:71-79.
11. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: Comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200:59-67.
12. Martin DR, Semelka RC, Chung JJ, et al. Sequential use of gadolinium chelate and mangafodipir trisodium for the assessment of focal liver lesions: Initial observations. Magn Reson Imaging 2000;18:955-963.
13. Lim KO, Stark DD, Leese PT, et al. Hepatobiliary MR imaging: First human experience with MnDPDP. Radiology 1991;178:79-82.
14. Rummeny EJ, Torres CG, Kurdziel JC, et al. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies. Acta Radiol 1997;38(4 pt 2):638-642.
15. Wang C. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas. Acta Radiol Suppl 1998;415:1-31.
16. Mathieu D, Coffin C, Kobeiter H, et al. Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir. J Magn Reson Imaging 1999;10:193-195.
17. Murakami T, Baron RL, Peterson MS, et al. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996;200:69-77.
18. Oudkerk M, Torres CG, Song B, et al. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: Multicenter study comparing MR and dual-phase spiral CT. Radiology 2002; (in press).
19. Rofsky NM, Weinreb JC, Bernardino ME, et al. Hepatocellular tumors: Characterization with Mn-DPDP-enhanced MR imaging. Radiology 1993;188:53-59.
20. Coffin CM, Diche T, Mahfouz A, et al. Benign and malignant hepatocellular tumors: Evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. Eur Radiol 1999;9:444-449.
21. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 1998;33:798-809.
22. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-796.
23. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999;6:282-291.
24. Spinazzi A, Lorusso V, Pirovano G, et al. Multihance clinical pharmacology: Biodistribution and MR enhancement of the liver. Acad Radiol 1998;5(suppl 1):S86-S89, discussion S93-S84.
25. Grazioli L, Kirchin M, Pirovano G, et al. MultiHance in the dynamic phase of contrast enhancement: A pictorial assessment. J Comput Assist Tomogr 1999;239(suppl 1):S61-S64.
26. Caudana R, Morana G, Pirovano GP, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)-Preliminary results of phase II clinical application. Radiology 1996;199:513-520.
27. Manfredi R, Maresca G, Baron RL, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 1999;9:704-710.
28. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: Morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001;221:731-739.
29. Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. Invest Radiol 1993;28:753-761.
30. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics, and MR imaging. Radiology 1995;195:785-792.
31. Enochs WS, Weissleder R. Organ-and-tissue directed MRI contrast agents. In: Edelman RR, Hesselink JR, Zlatkin MB, eds. Clinical Magnetic Resonance Imaging. Philadelphia: WB Saunders, 192-200.
32. Fahlvik AK, Klaveness J, Stark DD. Iron oxides as MR imaging contrast agents. J Magn Reson Imaging 1993;3:187-194.
33. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: Pharmacokinetics and toxicity. AJR Am J Roentgenol 1989;152:167-173.
34. Yamashita Y, Yamamoto H, Hirai A, et al. MR imaging enhancement with superparamagnetic iron oxide in chronic liver disease: Influence of liver dysfunction and parenchymal pathology. Abdom Imaging 1996;21:318-323.
35. Josephson L, Lewis J, Jacobs P, et al. The effects of iron oxides on proton relaxivity. Magn Reson Imaging 1988;6:647-653.
36. Fretz CJ, Elizondo G, Weissleder R, et al. Superparamagnetic iron oxide-enhanced MR imaging: Pulse sequence optimization for detection of liver cancer. Radiology 1989;172:393-397.
37. Schwartz LH, Seltzer SE, Tempany CM, et al. Superparamagnetic iron oxide hepatic MR imaging: Efficacy and safety using conventional and fast spin-echo pulse sequences. J Magn Reson Imaging 1995;5:566-570.
38. Kanematsu M, Hoshi H, Murakami T, et al. Fat-suppressed T2-weighted MR imaging of hepatocellular carcinoma and metastases: Comparison of conventional spin-echo, fast spin-echo, and echoplanar pulse sequences. J Magn Reson Imaging 1999;10:25-32.
39. Alger JR, Harreld JH, Chen S, et al. Time-to-echo optimization for spin echo magnetic resonance imaging of liver metastasis using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001;14:586-594.
40. Deckers F, Corthouts B, Nackaerts Y, et al. The influence of MR field strength on the detection of focal liver lesions with superparamagnetic iron oxide. Eur Radiol 1997;7:887-892.
41. Hahn PF, Saini S. Liver-specific MR imaging contrast agents. Radiol Clin North Am 1998;36:287-297.
42. Gandon Y, Heautot JF, Brunet F, et al. Superparamagnetic iron oxide: Clinical time-response study. Eur J Radiol 1991;12:195-200.
43. Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: A multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995;196:481-488.
44. Muller RD, Vogel K, Neumann K, et al. MRI with supermagnetic iron particles versus double-spiral CT in identification of malignant liver lesions. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1998;168:436-443.
45. Seneterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996;200:785-792.
46. Strotzer M, Gmeinwieser J, Schmidt J, et al. Diagnosis of liver metastases from colorectal adenocarcinoma. Comparison of spiral-CTAP combined with intravenous contrast-enhanced spiral-CT and SPIO-enhanced MR combined with plain MR imaging. Acta Radiol 1997;38:986-992.
47. Weissleder R. Liver MR imaging with iron oxides: Toward consensus and clinical practice, Radiology 1994;193:593-595.
48. Grangier C, Tourniaire J, Mentha G, et al. Enhancement of liver hemangiomas on T1-weighted MR SE images by superparamagnetic iron oxide particles. J Comput Assist Tomogr 1994;18:888-896.
49. Kopp AF, Laniado M, Dammann F, et al. MR imaging of the liver with Resovist: Safety, efficacy, and pharmacodynamic properties. Radiology 1997;204:749-756.
50. Kehagias DT, Gouliamos AD, Smyrniotis V, et al. Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A). J Magn Reson Imaging 2001;14:595-601.
51. Reimer P, Jahnke N, Fiebich M, et al. Hepatic lesion detection and characterization: Value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology 2000;217:152-158.
52. Saini S, Edelman RR, Sharma P, et al. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: Initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR Am J Roentgenol 1995;164:1147-1152.
53. Harisinghani MG, Saini S, Weissleder R, et al. Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood-pool contrast agent Code-7227. Radiology 1997;202:687-691.
54. Mergo PJ, Helmberger T, Nicolas AI, et al. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: A potential new sign for characterization of liver lesions. AJR Am J Roentgenol 1996;166:379-384.
55. Nguyen BN, Flejou JF, Terris B, et al. Focal nodular hyperplasia of the liver: A comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999;23:1441-1454.
56. Benhamou JP. Oral contraceptives and benign tumors of the liver. Gastroenterol Clin Biol 1997;21:913-915.
57. Craig JR, Peters RL, Edmonson HA. Tumors of the Liver and Intrahepatic Bile Ducts: Atlas of Tumors Pathology. Washington, DC: Armed Forced Institute of Pathology, 1989.
58. Cherqui D, Rahmouni A, Charlotte F, et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: A series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995;22:1674-1681.
59. Mathieu D, Rahmouni A, Anglade MC, et al. Focal nodular hyperplasia of the liver: Assessment with contrast-enhanced Turbo-FLASH MR imaging. Radiology 1991;180:25-30.
60. Carlson SK, Johnson CD, Bender CE, et al. CT of focal nodular hyperplasia of the liver. AJR Am J Roentgenol 2000;174:705-712.
61. Arbab AS, Ichikawa T, Araki T, et al. Detection of hepatocellular carcinoma and its metastases with various pulse sequences using superparamagnetic iron oxide (SHU-555-A). Abdom Imaging 2000;25:151-158.
62. Choi CS, Freeny PC. Triphasic helical CT of hepatic focal nodular hyperplasia: Incidence of atypical findings. AJR Am J Roentgenol 1998;170:391-395.
63. Boulahdour H, Cherqui D, Charlotte F, et al. The hot spot hepatobiliary scan in focal nodular hyperplasia. J Nucl Med 1993;34:2105-2110.
64. Paley MR, Mergo PJ, Torres GM, et al. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. AJR Am J Roentgenol 2000;175:159-163.
65. Grandin C, Van Beers BE, Robert A, et al. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration. J Comput Assist Tomogr 1995;19:412-418.
66. Grazioli L, Morana G, Caccia P, et al. MR imaging of FNH with Gd-BOPTA and SPIO: A comparison. In: ECR 2002. Vienna: Springer, 2002;283.
67. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990;11:787-797.
68. Arvanitaki M, Adler M. Nodular regenerative hyperplasia of the liver. A review of 14 cases. Hepatogastroenterology 2001;48:1425-1429.
69. Rougier P, Degott C, Rueff B, et al. Nodular regenerative hyperplasia of the liver. Report of six cases and review of the literature. Gastroenterology 1978;75:169-172.
70. Casillas C, Marti-Bonmati L, Galant J. Pseudotumoral presentation of nodular regenerative hyperplasia of the liver: Imaging in five patients including MR imaging. Eur Radiol 1997;7:654-658.
71. Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992;12:73-79.
72. Grazioli L, Federle MP, Brancatelli G, et al. Hepatic adenomas: Imaging and pathologic findings. Radiographics 2001;21:877-892. discussion 892-874.
73. Labrune P, Trioche P, Duvaltier I, et al. Hepatocellular adenomas in glycogen storage disease type I and III: A series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997;24:276-279.
74. Talente GM, Coleman RA, Alter C, et al. Glycogen storage disease in adults. Ann Intern Med 1994;120:218-226.
75. Shuangshoti S, Thaicharoen A. Hepatocellular adenoma in a betathalassemic woman having secondary iron overload. J Med Assoc Thai 1994;77:108-112.
76. Rubin RA, Lichtenstein GR. Hepatic scintigraphy in the evaluation of solitary solid liver masses. J Nucl Med 1993;34:697-705.
77. Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg 1988;208:558-564.
78. Nokes SR, Baker ME, Spritzer CE, et al. Hepatic adenoma: MR appearance mimicking focal nodular hyperplasia. J Comput Assist Tomogr 1988;12:885-887.
79. Gabata T, Matsui O, Kadoya M, et al. MR imaging of hepatic adenoma. AJR Am J Roentgenol 1990;155:1009-1011.
80. Paulson EK, McClellan JS, Washington K, et al. Hepatic adenoma: MR characteristics and correlation with pathologic findings. AJR Am J Roentgenol 1994;163:113-116.
81. Arrive L, Flejou JF, Vilgrain V, et al. Hepatic adenoma: MR findings in 51 pathologically proved lesions. Radiology 1994;193:507-512.
82. Chung KY, Mayo-Smith WW, Saini S, et al. Hepatocellular adenoma: MR imaging features with pathologic correlation. AJR Am J Roentgenol 1995;165:303-308.
83. Denys A, Arrive L, Servois V, et al. Hepatic tumors: Detection and characterization at 1-T MR imaging enhanced with AMI-25. Radiology 1994;193:665-669.
84. Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 1985;89:1132-1138.
85. Ribeiro A, Burgart LJ, Nagorney DM, et al. Management of liver adenomatosis: Results with a conservative surgical approach. Liver Transplant Surg 1998;4:388-398.
86. Choi BI, Han JK, Kim SH, et al. MR findings in liver adenomatosis. Gastrointest Radiol 1991;16:234-236.
87. Khan SS, Fink M, King S. Case report: Liver adenomatosis presenting as multiple calcified masses. Clin Radiol 1992;45:206-207.
88. Grazioli L, Federle MP, Ichikawa T, et al. Liver adenomatosis: Clinical, histopathologic, and imaging findings in 15 patients. Radiology 2000;216:395-402.
89. Chiche L, Dao T, Salame E, et al. Liver adenomatosis: Reappraisal, diagnosis, and surgical management: Eight new cases and review of the literature. Ann Surg 2000;231:74-81.
90. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
91. Ince N, Wands JR. The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999;340:798-799.
92. Zaman SN, Melia WM, Johnson RD, et al. Risk factors in development of hepatocellular carcinoma in cirrhosis: Prospective study of 613 patients. Lancet 1985;1:1357-1360.
93. Sadek AG, Mitchell DG, Siegelman ES, et al. Early hepatocellular carcinoma that develops within macroregenerative nodules: Growth rate depicted at serial MR imaging. Radiology 1995;195:753-756.
94. Rapaccini GL, Pompili M, Caturelli E, et al. Focal ultrasound lesions in liver cirrhosis diagnosed as regenerating nodules by fine-needle biopsy. follow up of 12 cases. Dig Dis Sci 1990;35:422-427.
95. Takayama T, Makuuchi M, Hirohashi S, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336:1150-1153.
96. Wanless IR. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 1995;22:983-993.
97. Krinsky GA, Lee VS, Theise ND, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: Prospective diagnosis with MR imaging and explantation correlation. Radiology 2001;219:445-454.
98. Lim JH, Cho JM, Kim EY, et al. Dysplastic nodules in liver cirrhosis: Evaluation of hemodynamics with CT during arterial portography and CT hepatic arteriography. Radiology 2000;214:869-874.
99. Earls JP, Theise ND, Weinreb JC, et al. Dysplastic nodules and hepatocellular carcinoma: Thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. Radiology 1996;201:207-214.
100. Matsui O, Kadoya M, Kameyama T, et al. Adenomatous hyperplastic nodules in the cirrhotic liver: Differentiation from hepatocellular carcinoma with MR imaging. Radiology 1989;173:123-126.
101. Edmonson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48900 necropsies. Cancer 1954;7:462-503.
102. Ishizaki M, Ashida K, Higashi T, et al. The formation of capsule and septum in human hepatocellular carcinoma. Virchows Arch 2001;438:574-580.
103. Tanaka M, Nakashima O, Wada Y, et al. Pathomorphological study of Kupffer cells in hepatocellular carcinoma and hyperplastic nodular lesions in the liver. Hepatology 1996;24:807-812.
104. Ebara M, Ohto M, Watanabe Y, et al. Diagnosis of small hepatocellular carcinoma: Correlation of MR imaging and tumor histologic studies. Radiology 1986;159:371-377.
105. Kadoya M, Matsui O, Takashima T, et al. Hepatocellular carcinoma: Correlation of MR imaging and histopathologic findings. Radiology 1992;183:819-825.
106. Yamashita Y, Fan ZM, Yamamoto H, et al. Spin-echo and dynamic gadolinium-enhanced FLASH MR imaging of hepatocellular carcinoma: Correlation with histopathologic findings. J Magn Reson Imaging 1994;4:83-90.
107. Winter TC 3rd, Takayasu K, Muramatsu Y, et al. Early advanced hepatocellular carcinoma: Evaluation of CT and MR appearance with pathologic correlation. Radiology 1994;192:379-387.
108. Ebara M, Fukuda H, Kojima Y, et al. Small hepatocellular carcinoma: Relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma. Radiology 1999;210:81-88.
109. Marti-Bonmati L. MR imaging characteristics of hepatic tumors. Eur Radiol 1997;7:249-258.
110. Earls JP, Rofsky NM, DeCorato DR, et al. Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: Optimization with a test examination and a power injector. Radiology 1997;202:268-273.
111. Frederick MG, McElaney BL, Singer A, et al. Timing of parenchymal enhancement on dual-phase dynamic helical CT of the liver: How long does the hepatic arterial phase predominate? AJR Am J Roentgenol 1996;166:1305-1310.
112. Yu JS, Kim KW, Kim EK, et al. Contrast enhancement of small hepatocellular carcinoma: Usefulness of three successive early image acquisitions during multiphase dynamic MR imaging. AJR Am J Roentgenol 1999;173:597-604.
113. Grazioli L, Olivetti L, Fugazzola C, et al. The pseudocapsule in hepatocellular carcinoma: Correlation between dynamic MR imaging and pathology. Eur Radiol 1999;9:62-67.
114. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: Correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 2000;35:25-34.
115. Grazioli L, Morana G, Schneider G, et al. Hypervascular hepatic lesions: Dynamic and late enhancement pattern with Gd-BOPTA. In: RSNA; 2001. Chicago: Radiology, 2001;105.
116. Kane PA, Ayton V, Walters HL, et al. MnDPDP-enhanced MR imaging of the liver. Correlation with surgical findings. Acta Radiol 1997;38(4 pt 2):650-654.
117. Ni Y, Marchal G, Yu J, et al. Experimental liver cancers: Mn-DPDP-enhanced rims in MR-microangiographic-histologic correlation study. Radiology 1993;188:45-51.
118. Helmberger TK, Laubenberger J, Rummeny E, et al. MRI characteristics in focal hepatic disease before and after administration of MnDPDP: Discriminant analysis as a diagnostic tool. Eur Radiol 2002;12:62-70.
119. Lim JH, Choi D, Cho SK, et al. Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: Importance of Kupffer cell number. Radiology 2001;220:669-676.
120. Tang Y, Yamashita Y, Arakawa A, et al. Detection of hepatocellular carcinoma arising in cirrhotic livers: Comparison of gadolinium- and ferumoxides-enhanced MR imaging. AJR Am J Roentgenol 1999;172:1547-1554.
121. Vogl TJ, Hammerstingl R, Schwarz W, et al. Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. Radiology 1996;198:881-887.
122. Kubaska S, Sahani DV, Saini S, et al. Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterization. Clin Radiol 2001;56:410-415.
123. Ward J, Guthrie JA, Scott DJ, et al. Hepatocellular carcinoma in the cirrhotic liver: Double-contrast MR imaging for diagnosis. Radiology 2000;216:154-162.
124. Pauleit D, Textor J, Bachmann R, et al. Hepatocellular carcinoma: Detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology 2002;222:73-80.
125. Ichikawa T, Federle MP, Grazioli L, et al. Fibrolamellar hepatocellular carcinoma: Imaging and pathologic findings in 31 recent cases. Radiology 1999;213:352-361.
126. McLarney JK, Rucker PT, Bender GN, et al. Fibrolamellar carcinoma of the liver: Radiologic-pathologic correlation. Radiographics 1999;19:453-471.
127. Burkill GJ, Mannion EM, Healy JC. Technical report: Lymph node enhancement at MRI with MnDPDP in primary hepatic carcinoma. Clin Radiol 2001;56:67-71.
128. Hanafusa K, Ohashi I, Himeno Y, et al. Hepatic hemangioma: Findings with two-phase CT. Radiology 1995;196:465-469.
129. van Leeuwen MS, Noordzij J, Feldberg MA, et al. Focal liver lesions: Characterization with triphasic spiral CT. Radiology 1996;201:327-336.
130. Kim T, Federle MP, Baron RL, et al. Discrimination of small hepatic hemangiomas from hypervascular malignant tumors smaller than 3 cm with three-phase helical CT. Radiology 2001;219:699-706.
131. Vilgrain V, Boulos L, Vullierme MP, et al. Imaging of atypical hemangiomas of the liver with pathologic correlation. Radiographics 2000;20:379-397.
132. Semelka RC, Cumming MJ, Shoenut JP, et al. Islet cell tumors: Comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression. Radiology 1993;186:799-802.
133. Larson RE, Semelka RC, Bagley AS, et al. Hypervascular malignant liver lesions: Comparison of various MR imaging pulse sequences and dynamic CT. Radiology 1994;192:393-399.
134. Mahfouz AE, Hamm B, Wolf KJ. Peripheral washout: A sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions. Radiology 1994;190:49-52.
135. Ferrucci JT. Liver tumor imaging. Current concepts. Radiol Clin North Am 1994;32:39-54.
136. Fong Y, Blumgart LH, Fortner JG, et al. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg 1995;222:426-434, discussion 434-427.
137. Wernecke K, Rummeny E, Bongartz G, et al. Detection of hepatic masses in patients with carcinoma: Comparative sensitivities of sonography, CT, and MR imaging. AJR Am J Roentgenol 1991;157:731-739.
138. Schulz W, Borchard F. The size of the liver metastases in a low metastatic count. A quantitative study of postmortem livers. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1992;156:320-324.
139. Semelka RC, Mitchell DG. Liver and biliary system. In: Edelman RR, Zlatkin MB, Hesselink JR, eds. Clinical Magnetic Resonance Imaging. Philadelphia: WB Saunders, 1996;1466-1512.
140. Semelka RC, Kelekis NL. Liver. In: Semelka RC, Ascher SM, Reinhold C, eds. MRI of the Abdomen and Pelvis. New York: Wiley-Liss, 1997;19-135.
141. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology 2001;218:27-38.
142. Outwater E, Tomaszewski JE, Daly JM, et al. Hepatic colorectal metastases: Correlation of MR imaging and pathologic appearance. Radiology 1991;180:327-332.
143. Semelka RC, Bagley AS, Brown ED, et al. Malignant lesions of the liver identified on T1- but not T2-weighted MR images at 1.5 T. J Magn Reson Imaging 1994;4:315-318.
144. Semelka RC, Cance WG, Marcos HB, et al. Liver metastases: Comparison of current MR techniques and spiral CT during arterial portography for detection in 20 surgically staged cases. Radiology 1999;213:86-91.
145. Reimer P, Rummeny EJ, Daldrup HE, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: Preliminary results with dynamic MR imaging. Eur Radiol 1997;7:275-280.
146. Ward J, Naik KS, Guthrie JA, et al. Hepatic lesion detection: Comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using altemative-free response receiver operating characteristic analysis. Radiology 1999;210:459-466.
147. Oudkerk M, van den Heuvel AG, Wielopolski PA, et al. Hepatic lesions: Detection with ferumoxide-enhanced T1-weighted MR imaging. Radiology 1997;203:449-456.
148. Semelka RC, Lee JK, Worawattanakul S, et al. Sequential use of ferumoxide particles and gadolinium chelate for the evaluation of focal liver lesions on MRI. J Magn Reson Imaging 1998;8:670-674.
149. Ward J, Robinson PJ. Combined use of MR contrast agents for evaluating liver disease. Magn Reson Imaging Clin N Am 2001;9:767-802, vi.
150. van Gansbeke D, Metens TM, Matos C, et al. Effects of AMI-25 on liver vessels and tumors on T1-weighted turbo-field-echo images: Implications for tumor characterization. J Magn Reson Imaging 1997;7:482-489.
151. Ros PR. Benign liver lesion. In: Gore RM, Levin MS, Laufer I, eds. Textbook of Gastrointestinal Radiology. Philadelphia: WB Saunders, 1994:1861-1896.
152. Reddy KR, Kligerman S, Levi J, et al. Benign and solid tumors of the liver: Relationship to sex, age, size of tumors, and outcome. Am Surg 2001;67:173-178.
153. Valls C, Rene M, Gil M, et al. Giant cavernous hemangioma of the liver: Atypical CT and MR findings. Eur Radiol 1996;6:448-450.
154. Mergo PJ, Ros PR. Benign lesions of the liver. Radiol Clin North Am 1998;36:319-331.
155. Weimann A, Ringe B, Klempnauer J, et al. Benign liver tumors: Differential diagnosis and indications for surgery. World J Surg 1997;21:983-990, discussion 990-981.
156. Semelka RC, Brown ED, Ascher SM, et al. Hepatic hemangiomas: A multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology 1994;192:401-406.
157. Soyer P, Gueye C, Somveille E, et al. MR diagnosis of hepatic metastases from neuroendocrine tumors versus hemangiomas: Relative merits of dynamic gadolinium chelate-enhanced gradient-recalled echo and unenhanced spin-echo images. AJR Am J Roentgenol 1995;165:1407-1413.
158. Yu JS, Kim MJ, Kim KW, et al. Hepatic cavernous hemangioma: Sonographic patterns and speed of contrast enhancement on multiphase dynamic MR imaging. AJR Am J Roentgenol 1998;171:1021-1025.
159. Whitney WS, Herfkens RJ, Jeffrey RB, et al. Dynamic breath-hold multiplanar spoiled gradient-recalled MR imaging with gadolinium enhancement for differentiating hepatic hemangiomas from malignancies at 1.5 T. Radiology 1993;189:863-870.
160. Bloom CM, Langer B, Wilson SR. Role of US in the detection, characterization, and staging of cholangiocarcinoma. Radiographics 1999;19:1199-1218.
161. Sherlock S, Dooley J. Disease of the Liver and Biliary System. London: Blackwell, 1997.
162. Fernandez MP, Redvanly RD. Primary hepatic malignant neoplasms. Radiol Clin North Am 1998;36:333-348.
163. Hashimoto T, Nakamura H, Hori S, et al. MR imaging of mixed hepatocellular and cholangiocellular carcinoma. Abdom Imaging 1994;19:430-432.
164. Vilgrain V, Van Beers BE, Flejou JF, et al. Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr 1997;21:59-65.
165. Klempnauer J, Ridder GJ, Werner M, et al. What constitutes longterm survival after surgery for hilar cholangiocarcinoma? Cancer 1997;79:26-34.
166. Okuda K, Kubo Y, Okazaki N, et al. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: A study of 57 autopsy-proven cases. Cancer 1977;39:232-246.
167. Maetani Y, Itoh K, Watanabe C, et al. MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol 2001;176:1499-1507.
168. Murakami T, Nakamura H, Tsuda K, et al. Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: Pathologic correlation study. J Magn Reson Imaging 1995;5:165-170.
169. Zhang Y, Uchida M, Abe T, et al. Intrahepatic peripheral cholangiocarcinoma: Comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr 1999;23:670-677.
170. Yoshida Y, Imai Y, Murakami T, et al. Intrahepatic cholangiocarcinoma with marked hypervascularity. Abdom Imaging 1999;24:66-68.
171. Vogl TJ, Hammerstingl R, Schwarz W, et al. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide Resovist versus gadolinium-DTPA in the same patient. Invest Radiol 1996;31:696-708.